Cytokinetics (CYTK) Net Equity Issued and Repurchased (2012 - 2024)
Cytokinetics (CYTK) posted quarterly Net Equity Issued and Repurchased of -$469.6 million for Q4 2024, down 388.3% year-over-year from $162.9 million in Q1 2024, and down 601.5% quarter-over-quarter from $93.6 million in Q1 2024.
Powered by 
Analysis
Cytokinetics (CYTK) Net Equity Issued and Repurchased (2012 - 2024) Analysis & Trends
Cytokinetics (CYTK) has reported Net Equity Issued and Repurchased for 9 consecutive years, with -$469.6 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Net Equity Issued and Repurchased fell 388.3% year-over-year to -$469.6 million; the TTM figure through Sep 2025 stood at -$469.6 million (down 283.06% YoY), while the FY2024 annual figure was $93.6 million, down 43.0% from the prior year.
- Net Equity Issued and Repurchased slipped to -$469.6 million in Q4 2024 per CYTK's latest filing, from $93.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $162.9 million in Q4 2023 and bottomed at -$469.6 million in Q4 2024.
- Historically, Net Equity Issued and Repurchased has averaged -$52.4 million across 3 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased plunged 538.6% — and 2024, when it plunged 388.3%.
- Cytokinetics' Net Equity Issued and Repurchased stood at -$50.0 million in 2020, then jumped by 425.78% to $162.9 million in 2023, then slumped by 388.3% to -$469.6 million in 2024.
- Business Quant data shows CYTK's Net Equity Issued and Repurchased at -$469.6 million in Q4 2024, $93.6 million in Q1 2024, and $162.9 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 93.64 Mn |
| Dec 31, 2023 | 162.92 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Sep 30, 2020 | -50.00 Mn |
| Sep 30, 2019 | 11.40 Mn |
| Jun 30, 2019 | 19.70 Mn |
| Mar 31, 2019 | 5.12 Mn |
| Sep 30, 2017 | -8,000.00 |
| Jun 30, 2017 | 82.80 Mn |
| Mar 31, 2017 | 17.36 Mn |
| Dec 31, 2015 | 8.67 Mn |
| Dec 31, 2014 | 10.00 Mn |
| Mar 31, 2014 | 39.87 Mn |
| Sep 30, 2013 | -33,000.00 |
| Jun 30, 2013 | 10.00 Mn |
| Dec 31, 2012 | 44.04 Mn |
| Jun 30, 2012 | 32.10 Mn |